Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. (Nasdaq: NAUT) is a life sciences company focused on developing a single-molecule protein analysis platform for proteomics research, which completed its business combination with ARYA Sciences Acquisition Corp III — sponsored by Perceptive Advisors — in June 2021. The company filed a DEFA14A, or Definitive Additional Proxy Materials, with the SEC on April 28, 2026 (accession 0001808805-26-000024), supplementing a previously filed proxy statement in connection with a shareholder vote. Perceptive Advisors, a healthcare-focused investment firm, served as sponsor for the ARYA III vehicle. Nautilus operates in the biotechnology and life-sciences tools sector. Visit SpacDesk and sign up for full filing history, shareholder meeting data, and sponsor analytics on NAUT and hundreds of other de-SPAC names.